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Peft Ventricular Systolic
ysfunction in Rheumatoid Disease
n Unrecognized Burden?
urbir S. Bhatia, MRCP,* Michael D. Sosin, MRCP,* Jeetesh V. Patel, PHD,*
arl A. Grindulis, FRCP,† Fazal H. Khattak, FRCP,† Elizabeth A. Hughes, BSC, FRCP,‡
regory Y. H. Lip, MD, FRCP, FACC, FESC,* Russell C. Davis, MRCP, MD*
irmingham and West Bromwich, United Kingdom
OBJECTIVES This study sought to ascertain whether left ventricular systolic dysfunction (LVSD) is more
common among clinic patients with rheumatoid disease (RD) compared with the general
population, and to assess the diagnostic utility of brain natriuretic peptide (BNP).
BACKGROUND Patients with RD are at increased risk of ischemic heart disease. However, there are few large
echocardiographic studies identifying cardiac dysfunction in RD. We hypothesized that
LVSD would be more prevalent in RD patients than in the general population.
METHODS A total of 226 hospital out-patients with RD (65% women) underwent clinical evaluation,
electrocardiography (ECG), echocardiography, and plasma BNP assay (218 patients).
Prevalence of LVSD was compared with local population estimates.
RESULTS Definite LVSD (left ventricular ejection fraction 40%) occurred in 5.3% of the RD group:
standardized prevalence ratio, 3.20; 95% confidence interval, 1.65 to 5.59. Median BNP
values were higher in patients with LVSD compared with those without: 16.6 pmol/l versus
8.5 pmol/l, p  0.005, although values between the two groups overlapped. One in nine
patients with an abnormal ECG had definite LVSD.
CONCLUSIONS Definite LVSD was three times more common in RD patients than in the general population.
Given the prognostic benefits of treating LVSD, echocardiographic screening of RD patients
with an abnormal ECG may be worthwhile. (J Am Coll Cardiol 2006;47:1169–74) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.059by the American College of Cardiology Foundation
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shronic heart failure (CHF) and left ventricular systolic
ysfunction (LVSD) are common conditions with poor
utcomes (1–3). Half of patients with LVSD are asymp-
omatic but are at increased risk (almost five-fold) of
eveloping CHF compared with patients without systolic
ysfunction (4). Angiotensin-converting enzyme inhibition
n asymptomatic LVSD delays progression to CHF (5),
aking its identification worthwhile.
Objective evidence of cardiac dysfunction is needed to
onfirm CHF because of difficulties in clinical diagnosis (6).
chocardiography is a practical confirmatory tool, but
ommunity access is currently limited. Brain natriuretic
eptide (BNP) distinguishes heart failure from other causes
f acute dyspnea (7), but its utility in chronic cases (8) and
symptomatic LVSD (9) is uncertain.
Rheumatoid disease (RD) is associated with increased
ardiovascular mortality, probably mediated by ischemic
eart disease (IHD) (10,11). Studies have reported an
ncreased risk of developing CHF in RD (12), although
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ccepted October 10, 2005.hey have not documented cardiac dysfunction. Diagnosing
HF in RD patients may be hindered by features of RD
tself, e.g., poor mobility.
We hypothesized that LVSD would be more common in
rheumatoid cohort compared with the general population.
e examined the predictors of LVSD in this population,
nd also assessed the potential usefulness of BNP measure-
ent in its identification.
ETHODS
onsecutive RD patients (American College of Rheuma-
ology diagnostic criteria [13]) over 40 years old attending a
ospital clinic were invited to participate. Participants
nderwent clinical assessment, 12-lead electrocardiography,
chocardiography, and venepuncture (non-fasting).
lectrocardiography. Major abnormalities were patholog-
cal Q waves, left bundle branch block, left ventricular
ypertrophy, atrial fibrillation or flutter. Other abnormali-
ies were considered minor.
chocardiography. Patients underwent two-dimensional
nd Doppler trans-thoracic echocardiography (Powervision
000, Toshiba, Tokyo, Japan) performed and reported by
ne investigator (G.S.B.). Left ventricular ejection fraction
LVEF) was assessed visually (14). The LVSD was defined
s LVEF 50%: definite and borderline LVSD described
VEF 40%, and between 40% and 50%, respectively. A
enior investigator (R.C.D.) reviewed all studies showing
VSD, with agreement for all definite LVSD cases. Pa-
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LVSD in Rheumatoid Disease March 21, 2006:1169–74ients with LVSD without documented coronary disease
ere offered coronary angiography.
The prevalence of LVSD was compared with that in the
eneral population in the West Midlands (1); R.C.D. was a
rincipal investigator of the previous study, using identical
chocardiographic definitions.
lood sampling. Routine laboratory assays (including
-reactive protein and erythrocyte sedimentation rate) were
erformed. Plasma was frozen at 70°C, with BNP immu-
oassay (ADVIA Centaur, Bayer Healthcare, Newbury,
ngland), performed subsequently in 218 patients by blinded
echnicians. Serum rheumatoid factor (by latex agglutination:
iokit, Instrumentation Laboratory, Barcelona, Spain) values
30 IU/l defined seropositivity.
D activity. Disease activity score-28 (DAS-28) was de-
ived from joint examination, subjective symptom severity,
nd erythrocyte sedimentation rate (15).
tatistical analysis. Comparisons of normally and non-
ormally distributed data (determined by the Kolmogorov-
mirnov test) were made using the Student t test (presented
s mean [SD]) and Mann-Whitney test (presented as
edian [IQR]), respectively. Categorical data were com-
ared using the chi-square test; 95% confidence intervals
CI) for prevalences were calculated. Prevalence of LVSD
as stratified by gender, and age-adjusted comparisons were
ade. Predictors of LVSD (p 0.05 on univariate analysis)
ere included in a multivariate analysis of overall LVSD
sing stepwise logistic regression. Receiver operator charac-
eristic curves studied diagnostic performance of BNP. Data
ere analyzed using SPSS version 10.0 for Windows (SPSS
nc., Chicago, Illinois). The study was approved by the local
esearch ethics committee; all patients gave written in-
ormed consent.
ESULTS
emographics. Of 304 patients initially invited, 226
74%) patients participated; non-participants were older
mean age, 63.6 years; standard deviation, 8.2). Table 1
llustrates baseline differences between the RD and previ-
usly reported comparator populations (1).
D activity, treatment, and extra-articular symptoms. Table
lists RD activity: 161 patients (71%) were seropositive,
nd examination showed nodules in 27%. Almost one-half
f all participants (107 of 226) reported restricted mobility
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  chronic heart failure
CI  confidence interval
ECG  electrocardiogram/electrocardiography
IHD  ischemic heart disease
LVEF  left ventricular ejection fraction
LVSD  left ventricular systolic dysfunction
RD  rheumatoid diseaseaused by arthropathy, with 16% limited by dyspnea. Me-
a
Mian disease duration was 10 years (range, 4 to 16 years); 126
f 226 were taking corticosteroids, and 103 of 226 (45.6%)
ere taking methotrexate.
revalence of LVSD. Table 2 characterizes individuals
ith LVSD. Definite LVSD was significantly more preva-
ent in RD (p  0.001): 5.3% (95% CI, 2.4% to 8.2%)
ersus 1.8% (95% CI, 1.4% to 2.2%). Any LVSD (i.e.,
efinite  borderline) was also more frequent: 10.2% (95%
I, 6.2% to 14.1%) in RD versus 5.3% (95% CI, 4.6% to
.0%, p  0.01). Most patients with LVSD were male (14
f 23, 61%), and all 23 were white; LVSD was more
ommon in men (14 of 80, 17.5%) than women (9 of 146,
.2%), p  0.01. Approximately half (11 of 23) had clinical
vidence of IHD, but only 8 of 23 had had previous
ocumentation of this. Coronary revascularization had been
reviously performed in 4 of 23. Only 5 of 19 patients
onsented to coronary angiography. Significant coronary
isease was identified in two cases (Patients #1 and #6,
able 2A), whereas coronary vessels appeared normal in the
ther three (Patient #9 of Table 2A, and Patients #6 and
10 of Table 2B).
Age-standardized prevalence ratios for LVSD in RD are
hown in Table 3. Any and definite LVSD were signifi-
antly more frequent in RD, with ratios of 1.92 and 3.20,
espectively.
NP. Median levels (Fig. 1) were significantly higher in
hose with LVSD, in whom BNP values ranged from 1.1 to
81.0 pmol/l. Receiver operator characteristic curves (not
able 1. Baseline Demographic and Clinical Differences
etween RD and Comparator Populations
Characteristic RD
General
Population p
umber 226 3,960
ge band, number (%) 0.001
54 45 (19.9) 1,314 (33.2)
55–64 86 (38.1) 1,194 (30.2)
65 95 (42.0) 1,452 (36.7)
ean age, yrs (SD) 62.1 (9) 61.0 (11) NS
ale (%) 80 (35.4) 1,964 (49.6) 0.0001
on-white (%) 21 (9.3) 105 (2.7) 0.0001
ast medical history
Previous MI (%) 13 (5.8) 211 (5.3) 0.7829
Angina (%) 21 (9.3) 285 (7.2) 0.2392
Hypertension (%) 84 (37.2) 964 (24.3) 0.0001
Diabetes (%) 19 (8.4) 157 (4.0) 0.0012
Ever smoked (%) 147 (65) 2,284 (57.8) 0.0290
rug therapy (%)
ACE inhibitors 22 (9.7) 223 (5.6) 0.0105
Beta-blockers 27 (11.9) 358 (9.0) 0.1414
Calcium blockers 31 (13.7) 345 (8.7) 0.0104
Diuretics 51 (22.6) 515 (13.0) 0.0001
Aspirin 28 (12.4) 402 (10.2) 0.2811
isease activity parameter
Median CRP (mg/l) 14.0 (IQR 16.5)
Median ESR (mm/h) 20.0 (IQR 25.8)
Mean DAS-28 3.56 (SD 1.22)
CE  angiotensin-converting enzyme; CRP  C-reactive protein; DAS  disease
ctivity score; ESR  erythrocyte sedimentation rate; IQR  interquartile range;
I  myocardial infarction; RD  rheumatoid disease; SD  standard deviation.
Table 2. Characteristics of Subjects With Definite and Borderline LVSD
Patient Age (yrs) Gender Past Medical History ECG Findings BNP (pmol/l) Symptoms/Signs
A. Definite LVSD
1 55 M Ex-smoker SR inferior Q waves 11.0 Dyspnea on moderate exertion
2 72 F BP DM ex-smoker SR anterior Q waves 119.9 Dyspnea on walking uphill
COPD LVH LVH, S4 gallop
3 66 F BP SR LBBB 22.5 Dyspnea on walking uphill
4 73 F BP smoker SR poor R-wave progression 381.0 Dyspnea on mild exertion
On loop diuretic Fluid overload evident
5 76 M Ex-smoker COPD SR lateral T-wave inversion 16.6 Dyspnea on mild exertion, PND
On loop diuretic Fluid overload evident
6 56 M BP DM chol ex-smoker SR lateral T-wave inversion 3.3 Limited by intermittent claudication
PVD
On ARB
7 72 M MI chol ex-smoker SR LBBB 105.8 Dyspnea on walking uphill
On loop diuretic and ACEI S4 gallop, fluid overload evident
8 71 F MI-CABG chol SR dominant 37.4 Dyspnea on walking uphill
On ACEI R-wave anteriorly lateral T-wave inversion Fluid overload evident
9 66 F Ex-smoker SR LBBB 8.3 Dyspnea on walking uphill
10 77 F MI PVD ex-smoker SR anterior Q waves 54.0 Mobility restricted by arthralgia
On loop diuretic and ACEI RBBB
11 72 M BP smoker COPD SR LVH NA Dyspnea on walking uphill
On loop diuretic and ACEI Fluid overload evident
12 63 M CABG ex-smoker SR bifascicular block 15.3 Dyspnea on mild exertion, PND
COPD Fluid overload evident
B. Borderline LVSD
1 61 M Previous coronary angioplasty
ex-smoker
SR LBBB 3.1 Limited by angina
Pulmonary fibrosis Dyspnea on mild exertion
On beta-blocker
2 65 M BP AF ex-smoker AF LVH 14.7 Fatigue
On beta-blocker
3 55 F Smoker SR LBBB 20.6 Dyspnea on moderate exertion, relieved by bronchodilators
Asthma
4 59 M Nil of note SR NA Limited by arthralgia
5 61 M Smoker SR inferior 31.7 Limited by arthralgia
Q waves
6 52 M Ex-smoker SR anterior 1.1 Limited by arthralgia
Pulmonary fibrosis T-wave inversion Dyspnea on walking upstairs
7 58 F Paroxysmal AF smoker SR 5.9 Limited by dyspnea/fatigue
8 56 M Aortic dissection repair SR LBBB 25.8 Limited by dyspnea, angina
Angina BP chol LVH
On ARB, beta-blocker
9 64 M MI chol ex-smoker SR inferior 20.4 Dyspnea on mild exertion
Q waves
10 48 F Nil of note SR LBBB 8.7 No symptoms
11 67 M MI CABG PVD chol ex-smoker SR 11.4 Limited by intermittent claudication
On loop diuretic, ACEI, beta-blocker
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB  angiotensin receptor blocker; BNP  brain natriuretic peptide; BP  hypertension; CABG  coronary artery bypass graft; CAD  coronary artery
disease; chol  hypercholesterolemia; COPD  chronic obstructive pulmonary disease; DM  diabetes mellitus; L/RBBB  left/right bundle branch block; LVH  left ventricular hypertrophy; MI  myocardial infarction; NA  not
available; PVD  peripheral vascular disease; SR  sinus rhythm; other abbreviations as in Table 1.
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LVSD in Rheumatoid Disease March 21, 2006:1169–74hown) for BNP across the whole RD population showed
n area under the curve for any LVSD of only 0.69 (95% CI,
.55 to 0.83), whereas that for definite LVSD was 0.78
95% CI, 0.62 to 0.95).
lectrocardiographic findings and LVSD. Of 226 RD
atients, 108 (48%) had electrocardiographic (ECG) abnor-
alities. All 12 with definite LVSD, and 8 of 11 with
orderline LVSD had ECG abnormalities (sensitivity,
7%). Of those with LVSD, 14 of 23 (61%) had major
bnormalities. Table 4 lists the performance of ECG in
dentifying LVSD.
redictors of LVSD. Factors associated with any LVSD
mong RD patients are shown in Table 5. On multivariate
nalysis, only abnormal ECG (odds ratio, 8.778; 95% CI,
.901 to 40.530; p  0.005), previous myocardial infarction
odds ratio, 4.939; 95% CI, 1.046 to 23.316; p  0.044),
nd BNP (odds ratio, 1.030; 95% CI, 1.001 to 1.059; p 
.043) were independent predictors.
ISCUSSION
he prevalence of echocardiographic LVSD was signifi-
antly higher in the RD cohort compared with the general
opulation, supporting recent epidemiologic data (12), and
lso providing a likely mechanism for CHF. The preva-
ence of definite LVSD (LVEF 40%) was three times
ore frequent in RD. This is important given the
educed survival associated with LVSD, and the fact that
any therapeutic studies for LVSD used a definition of
VEF 40%.
Previous echocardiographic studies have been smaller,
ave recruited younger patients, and have excluded those
ith cardiac risk factors (10). Most have shown no differ-
able 3. Age-Standardized Prevalence Ratios for LVSD in RD
tratified by Gender
Standardized Prevalence Ratio
(95% CI) in RD
efinite LVSD
Men 2.41 (0.89–5.25)
Women 4.74 (1.74–10.3)
Men and women 3.20 (1.65–5.59)
ny LVSD
Men 2.36 (1.29–9.95)
Women 1.48 (0.68–2.81)
Men and women 1.92 (1.22–2.88)
I  confidence interval; LVSD  left ventricular systolic dysfunction; RD 
heumatoid disease.
Table 4. Performance of the ECG in Identifyi
Characteristic
Sensitivity, % (95% CI) 20
Specificity, % (95% CI) 115
Positive predictive value, % (95% CI) 20
Negative predictive value, % (95% CI) 115CI confidence interval; ECG electrocardiogram; LVEF left
dysfunction; RD  rheumatoid disease.nces in systolic function between RD patients and control
atients.
We have presented data from older patients in a real-
orld setting. Clearly, important demographic differences
xisted between the two cohorts. The RD cohort was mostly
emale (65%), reflecting the typical excess in women. Male
ender was associated with LVSD, and a higher proportion
f males would have increased its overall prevalence. There
ere also significantly higher rates of hypertension, diabetes,
nd tobacco use among the RD group, which clearly could
ave effected the increased prevalence of LVSD. The increased
revalence of these factors in RD is noteworthy. For example,
igher rates of hypertension in RD may be treatment related
16). Furthermore, tobacco use may increase the risk of
eveloping RD itself (17), possibly underlying some in-
reased susceptibility to IHD.
tiology of LVSD. Reported myocardial infarction was an
ndependent predictor of LVSD. We found clinical evi-
ence of IHD in almost 50% of cases; unfortunately, not
ll patients without documented coronary disease ac-
epted coronary angiography. Interestingly, however, three
atients who did consent had angiographically normal
oronaries. This raises the possibility of underlying myocar-
itis (18) or microvascular disease. Myocardial biopsy data
igure 1. Box plots showing median plasma brain natriuretic peptide
BNP) levels (horizontal bars) for normal left ventricular (LV) function
ersus left ventricular systolic dysfunction (LVSD). Median BNP  8.5
mol/l (interquartile range, 8.8) in those with normal LV function versus
6.6 pmol/l (interquartile range, 26.1) in those with LVSD. LVEF  left
entricular ejection fraction.
VSD in RD Patients
y LVSD
F <50%)
Definite LVSD
(LVEF <40%)
7.0 (73.2–1.00) 12/12, 100
56.7 (49.8–63.5) 118/214, 55.1 (48.5–61.8)
18.5 (11.1–25.8) 12/108, 11.1 (5.2–17.0)
97.5 (94.6–100 ) 118/118, 100ng L
An
(LVE
/23, 8
/203,
/108,
/118,ventricular ejection fraction; LVSD left ventricular systolic
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March 21, 2006:1169–74 LVSD in Rheumatoid Diseaser, less invasively, positron emission tomography or cardiac
agnetic resonance imaging would be of interest here.
Adding to epidemiologic data associating RD and IHD,
nteresting pathophysiological similarities between rheuma-
oid and atherosclerotic inflammation exist (19). However,
tudies detailing the coronary anatomy and nature of lesions
n rheumatoid patients with IHD are surprisingly scarce, yet
ould be most valuable.
CG as a predictor of LVSD. The presence of ECG
bnormalities independently predicted LVSD. As in the
eneral population, the absence of major abnormalities
akes definite LVSD unlikely (negative predictive value,
7%), whereas a completely normal ECG virtually rules out
he possibility of definite LVSD (negative predictive value,
00%). Thus, when confronted by RD patients with possi-
le heart failure, rheumatologists should make ECG a
rst-line investigation.
NP—a useful test? The BNP values overlapped in RD
atients with and without LVSD despite a significant differ-
nce between median values. Receiver operator characteristic
urve analysis indicated poor performance in identifying any
VSD. Elevated BNP levels are not specific for LVSD, and
ay be reduced by concomitant diuretic and angiotensin-
onverting enzyme inhibitor therapy, limiting sensitivity.
creening for LVSD. Identifying patients at risk of devel-
ping CHF attributable to LVSD is important given the
enefits of angiotensin-converting enzyme inhibitors. Fur-
hermore, some patients could benefit from further investi-
ation and therapy (e.g., prognostic revascularization).
However, community echocardiographic screening is costly,
nd should probably be restricted to high-risk groups. Given
he overall prevalence of LVSD reported, evaluating a
creening strategy might be worthwhile in RD patients.
ccording to our data, one in nine RD patients with any
CG abnormality, and almost one in six with a major
bnormality, would be expected to have definite LVSD.
he BNP assay—less widely available—would not have any
dvantage over ECG in targeting RD patients for echocar-
iography.
tudy limitations. We acknowledge the difficulties in
omparing clinic and community populations; RD patients
able 5. Features Associated With LVSD in RD Patients on
nivariate Analysis
Variable
Odds
Ratio
95% Confidence
Interval p
resence of ECG abnormalities 8.3 2.4–28.9 0.001
eported MI 6.8 2.0–22.9 0.002
eported angina 4.4 1.5–12.9 0.006
estricted mobility caused by dyspnea 3.4 1.3–8.9 0.011
eripheral edema evident 3.4 1.4–8.6 0.009
ale gender 3.2 1.3–7.8 0.010
emoglobin 1.4 1.0–2.0 0.035
lucose 1.2 1.0–1.4 0.022
rain natriuretic peptide 1.04 1.02–1.07 0.001
bbreviations as in Table 4.reated solely in the community may be expected to have lessevere disease and fewer co-morbid illnesses. However, with
arlier implementation of disease-modifying medication
and surveillance for side effects), most patients with proven
D may now be under hospital supervision. Therefore, our
ndings are especially applicable to this setting.
ONCLUSIONS
rognostically relevant LVSD is common in hospital clinic
atients with RD. A normal ECG effectively rules out
VSD, and ECG should be the first-line investigation for
atients with suspected heart failure. A role for BNP is less
lear in this setting. Echocardiographic screening for LVSD
mong RD patients with abnormal ECG results is likely to
e valuable and warrants further evaluation.
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